Citation Impact
Citing Papers
CSF tau/Aβ 42 ratio for increased risk of mild cognitive impairment
2007
Management of Helicobacter pylori infection—the Maastricht V/Florence Consensus Report
2016 Standout
Plasma β-amyloid in Alzheimer’s disease and vascular disease
2016 StandoutNobel
Mapping brain asymmetry
2003 Standout
Cerebrospinal Fluid Biomarkers Predict Decline in Subjective Cognitive Function over 3 Years in Healthy Elderly
2007
The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics
2011 Standout
Tau-mediated neurodegeneration in Alzheimer's disease and related disorders
2007 Standout
Diagnosis-Independent Alzheimer Disease Biomarker Signature in Cognitively Normal Elderly People
2010
Current state and future directions of neurochemical biomarkers for Alzheimer's disease
2007
Plasma phospholipids identify antecedent memory impairment in older adults
2014
Advances in the development of biomarkers for Alzheimer’s disease: from CSF total tau and Aβ1–42 proteins to phosphorylated tau protein
2003
Biological markers for therapeutic trials in Alzheimer’s disease
2003
Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke
2001
A Voxel-Based Morphometric Study of Ageing in 465 Normal Adult Human Brains
2001 Standout
Amyloid β Protein Dimer-Containing Human CSF Disrupts Synaptic Plasticity: Prevention by Systemic Passive Immunization
2008
Cortical Hubs Revealed by Intrinsic Functional Connectivity: Mapping, Assessment of Stability, and Relation to Alzheimer's Disease
2009 Standout
Amyloid Oligomers Exacerbate Tau Pathology in a Mouse Model of Tauopathy
2012 Standout
Cerebrospinal fluid protein biomarkers for Alzheimer’s disease
2004
Alzheimer's disease
2011 Standout
Mild Cognitive Impairment
2011 Standout
CSF and MRI markers independently contribute to the diagnosis of Alzheimer's disease
2007
The role of biological markers in the early and differential diagnosis of Alzheimer’s disease
2002
Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria
2007 Standout
Amyloid-β protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory
2008 Standout
CSF markers for incipient Alzheimer's disease
2003
Elevated levels of phosphorylated neurofilament proteins in cerebrospinal fluid of Alzheimer disease patients
2002
Gold nanoparticles in nanomedicine: preparations, imaging, diagnostics, therapies and toxicity
2009 Standout
Decreased β-Amyloid1-42and Increased Tau Levels in Cerebrospinal Fluid of Patients With Alzheimer Disease
2003
Combined CSF tau, p-tau181 and amyloid-β 38/40/42 for diagnosing Alzheimer’s disease
2009
CSF Biomarkers for Alzheimer’s Disease: Levels of β-Amyloid, Tau, Phosphorylated Tau Relate to Clinical Symptoms and Survival
2006
Cerebrospinal fluid -amyloid 1-42 concentration may predict cognitive decline in older women
2006
Single-molecule enzyme-linked immunosorbent assay detects serum proteins at subfemtomolar concentrations
2010 Standout
Insights into the ageing mind: a view from cognitive neuroscience
2004 Standout
Plasma and Cerebrospinal Fluid Levels of Amyloid β Proteins 1-40 and 1-42 in Alzheimer Disease
2000
Molecular, Structural, and Functional Characterization of Alzheimer's Disease: Evidence for a Relationship between Default Activity, Amyloid, and Memory
2005 Standout
Mapping cortical change across the human life span
2003 Standout
Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
2009 Standout
Subgroups of Alzheimer's disease based on cerebrospinal fluid molecular markers
2005
Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers
2013 Standout
Alzheimer's disease
2006 Standout
Alzheimer's disease
2016 Standout
Age-related cognitive decline, mild cognitive impairment or preclinical Alzheimer's disease?
2000
Anti-Aβ Drug Screening Platform Using Human iPS Cell-Derived Neurons for the Treatment of Alzheimer's Disease
2011 StandoutNobel
Post-translational modifications of tau protein in Alzheimer’s disease
2004
Autobiographical memory retrieval in patients with Alzheimer's disease
2010
Alzheimer's Disease
2010 Standout
CSF biomarkers for mild cognitive impairment and early Alzheimer's disease
2004
Tau protein isoforms, phosphorylation and role in neurodegenerative disorders11These authors contributed equally to this work.
2000 Standout
The Endophenotype Concept in Psychiatry: Etymology and Strategic Intentions
2003 Standout
Alzheimer's Disease
2004 Standout
Amnestic MCI or prodromal Alzheimer's disease?
2004
Cerebrospinal fluid tau and Aβ42 as predictors of development of Alzheimer's disease in patients with mild cognitive impairment
1999
A Bayesian model of shape and appearance for subcortical brain segmentation
2011 Standout
Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study
2009
Gold nanoparticles in biomedical applications: recent advances and perspectives
2011 Standout
Differential Diagnosis of Alzheimer Disease With Cerebrospinal Fluid Levels of Tau Protein Phosphorylated at Threonine 231
2002
Recommendations for the diagnosis and management of Alzheimer's disease and other disorders associated with dementia: EFNS guideline
2007
Mild cognitive impairment as a diagnostic entity
2004 Standout
Large-scale brain networks and psychopathology: a unifying triple network model
2011 Standout
The Brain's Default Network
2008 Standout
Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders
2011 Standout
Beta Amyloid in Alzheimer's Disease: Increased Deposition in Brain Is Reflected in Reduced Concentration in Cerebrospinal Fluid
2009
The molecular pathology of Alzheimer's disease
1991 Standout
Cerebral amyloid angiopathy in the elderly
2011
Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects
2009 Standout
Biosensing with plasmonic nanosensors
2008 Standout
Diagnostic Accuracy of ELISA and xMAP Technology for Analysis of Amyloid β42 and Tau Proteins
2007
Vitamin E and Donepezil for the Treatment of Mild Cognitive Impairment
2005 Standout
Exercise and Physical Activity for Older Adults
2009 Standout
Simultaneous Measurement of β-Amyloid(1–42), Total Tau, and Phosphorylated Tau (Thr181) in Cerebrospinal Fluid by the xMAP Technology
2004
Neurodegenerative Tauopathies
2001 Standout
Initial CSF total tau correlates with 1-year outcome in patients with traumatic brain injury
2006
Dynamics of Gray Matter Loss in Alzheimer's Disease
2003
Practice parameter: Management of dementia (an evidence-based review) [RETIRED]
2001 Standout
Multifunctional Inorganic Nanoparticles for Imaging, Targeting, and Drug Delivery
2008 Standout
Practice parameter: Diagnosis of dementia (an evidence-based review)
2001
Diagnostic impact of CSF biomarkers for Alzheimer's disease in a tertiary memory clinic
2014
The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
2011 Standout
Core candidate neurochemical and imaging biomarkers of Alzheimer's disease
2007
Gold Nanoparticles in Chemical and Biological Sensing
2012 Standout
Cerebrospinal fluid Aβ42 is the best predictor of clinical progression in patients with subjective complaints
2012
The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
2011 Standout
Physical Activity and Public Health in Older Adults
2007 Standout
Impact of chronic Helicobacter pylori infection on Alzheimer's disease: preliminary results
2011
Nonoverlapping but synergetic tau and APP pathologies in sporadic Alzheimer’s disease
2002
Nanostructures in Biodiagnostics
2005 Standout
Nanoparticle-based detection in cerebral spinal fluid of a soluble pathogenic biomarker for Alzheimer's disease
2005
Reducing Endogenous Tau Ameliorates Amyloid ß-Induced Deficits in an Alzheimer's Disease Mouse Model
2007 StandoutScience
Biological Markers in Alzheimer Disease
2002
Dynamic mapping of human cortical development during childhood through early adulthood
2004 Standout
APOE ε4 allele is associated with reduced cerebrospinal fluid levels of Aβ42
2004
Meta-Analysis: High-Dosage Vitamin E Supplementation May Increase All-Cause Mortality
2005 Standout
LEF-1 is crucial for neutrophil granulocytopoiesis and its expression is severely reduced in congenital neutropenia
2006 Standout
Works of P.P. De Deyn being referenced
Improved discrimination of AD patients using β-amyloid (1-42) and tau levels in CSF
1999